Barrett's oesophagus: Optimal strategies for prevention and treatment

Drugs

Volumn 63, Issue 6, 2003, Pages 555-564

  Fass, Ronnie ^a   Sampliner, Richard E ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; OMEPRAZOLE; RABEPRAZOLE; RANITIDINE;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER SCREENING; CANCER SURVIVAL; CARCINOGENESIS; DISEASE ASSOCIATION; DISEASE COURSE; DYSPLASIA; ENDOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; ESOPHAGUS MUCOSA; ESOPHAGUS RESECTION; EVIDENCE BASED MEDICINE; GASTROESOPHAGEAL REFLUX; HUMAN; REVIEW; RISK FACTOR;

ADENOCARCINOMA; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; PROTON PUMPS;

EID: 0037243474     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363060-00003     Document Type: Review

References (100)

1. Sampliner RE, and The Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 1998; 93: 1028-32
2. Blot W, Devesa S, Kneller R, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991: 265: 1287-9
3. Devesa S, Blot W, Fraumeni J. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-53
4. Bytzer P, Christensen PB, Damkier P, et al. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999 Jan: 94 (1): 86-91
5. Spechler SJ, Goyal R. Barrett's esophagus. N Engl J Med 1986; 315: 362-71
6. Spechler SJ. The columnar lined oesophagus: a riddle wrapped in a mystery inside an enigma. Gut 1997; 41: 710-1
7. Kim R, Weissfeld J, Reynolds J, et al. Etiology of Barrett's metaplasia and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 1997; 6: 369-77
8. Cameron A, Zinsmeister A, Ballard D, et al. Prevalence of columnar-lined (Barrett's) esophagus: comparison of population based clinical and autopsy findings. Gastroenterology 1990; 99: 918-27
9. Cameron A, Lomboy C, Barrett's esophagus: age, prevalence and extent of columnar epithelium. Gastroenterology 1992; 103: 1241-5
10. GOSPE, 'Esofago' GOplSdPd. Barrett's esophagus: epidemiological and clinical results of a multicentric survey. Int J Cancer 1991; 48: 364-8
11. Sarr M, Hamilton S, Marrone G, et al. Barrett's esophagus: it's prevalence and association with adenocarcinoma in patients with symptoms of gastroesophageal reflux. Am J Surg 1985; 149: 187-93
12. Winters C, Spurling T, Chobanian S, et al. Barrett's esophagus: a prevalent occult complication of gastroesophageal reflux disease. Gastroenterology 1987: 92: 118-24
13. Bersentes K, Fass R, Padda S, et al. Prevalence of Barrett's esophagus in Hispanics is similar to Caucasians. Dig Dis Sci 1998; 43: 1038-41
14. Sanfey H, Hamilton S, Smith R, et al. Carcinoma arising in Barrett's esophagus. Surg Gynecol Obstet 1985: 161: 570-4
15. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31
16. Johnson D, Winters C, Spurling T, et al. Esophageal acid sensitivity in Barrett's esophagus. J Clin Gastroenterol 1987; 9: 23-7
17. Grade A, Pulliam G, Johnson C, et al. Reduced chemoreceptor sensitivity in patients with Barrett's esophagus may be related to age and not to the presence of Barrett's epithelium. Am J Gastroenterol 1997; 92: 2040-3
18. Martinez S, Malagon I, Garewal HS, et al. Non-erosive reflux disease (NERD): is it really just a mild form of gastroesophageal reflux disease (GERD) [abstract 424]? Gastroenterology 2001; 120: 2163
19. Mulholland M, Reid BJ, Levine D, et al. Elevated gastric acid secretion in patients with Barrett's metaplasia epithelium. Dig Dis Sci 1989; 42: 1853-8
20. Collen M, Lewis J, Benjamin S. Gastric acid hypersecretion in refractory gastroesophageal reflux disease. Gastroenterology 1990; 98: 654-61
21. Collen M, Johnson D. Correlation between basal acid output and daily ranitidine dose required for therapy in Barrett's esophagus. Dig Dis Sci 1992; 37: 570-6
22. Hirschowitz B. Gastric acid and pepsin secretion in patients with Barrett's esophagus and appropriate controls. Dig Dis Sci 1996: 41: 1384-91
23. Fass R, Hell R, Garewal HS, et al. Correlation of oesophageal acid exposure with Barrett's oesophagus length. Gut 2001; 48: 310-3
24. Oberg S, DeMeester T, Peters J, et al. The extent of Barrett's esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure. J Thorac Cardiovasc Surg 1999; 117: 572-80
25. Tharatson E, Martinez S, Pulliam G, et al. Correlation between the height of abnormal acid reflux and the length of Barrett's esophagus [abstract 230]. Gastroenterology 2000; 118: 1376
26. Singh P, Taylor R, Colin-Jones D. Esophageal motor dysfunction and acid exposure in reflux esophagitis are more severe if Barrett's metaplasia is present. Am J Gastroenterol 1994, 89: 349-56
27. Oberg S, Ritter P, Crookes P, et al. Gastroesophageal reflux disease and mucosal injury with emphasis on short segment Barrett's esophagus and duodenogastroesophageal reflux. J Gastrointest Surg 1998; 2: 547-54
28. Mittal R, Holloway R, Penagini R, et al. The esophagogastric junction. N Engl J Med 1997; 336: 924-32
29. Hill L, Kozarek R, Kraemer S, et al. The gastroesophageal flap valve: in vitro and in vivo observations. Gastrointest Endosc 1996; 44: 541-7
30. Sloan S, Rademaker A, Kahrilas P. Determinants of gastroesophageal junction incompetence: hiatal hernia, lower esophageal sphincter, or both? Ann Intern Med 1992; 117: 977-82
31. Cameron A. Barrett's esophagus: prevalence and size of Natal hernia. Am J Gastroenterol 1999; 94: 2054-9
32. Al-Mutawa T, Malagon I, Garewal HS, et al. Correlation between the length of Barrett's esophagus and the size of hiatal hernia [abstract 154]. Gastrointest Endosc 2001; 53: 4155
33. Lieberman D, Oehlke M, Helfand M, et al. Risk factors for Barrett's esophagus in community-based practice. Am J Gastroenterol 1997; 92: 1293-7
34. Sampliner RE, Fennerty MB, Garewal HS. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results. Gastrointest Endosc 1996; 44: 532-5
35. Romero Y, Cameron A, Locke GI, et al. Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 1997; 113: 1449-56
36. Gelfand M. Barrett's esophagus in sexagenarian identical twins. J Clin Gastroenterol 1983; 5: 251-3
37. Prior A, Whorwell P. Familial Barrett's oesophagus? Hepatogastroenterology 1986; 33: 86-7
38. Crabb D, Berk M, Hall T, et al. Familial gastroesophageal reflux and development of Barrett's esophagus. Ann Intern Med 1985; 103: 52-4
39. Gillen P, Keeling P, Byrne J, et al. Experimental columnar metaplasia in the canine oesophagus. Br J Surg 1988; 75: 113-5
40. Fennerty MB, Sampliner RE, Garewal HS. Review article: Barrett's esophagus: cancer risk, biology and therapeutic management. Aliment Pharmacol Ther 1993; 7: 339-45
41. Vaezi M, Richter J. Role of acid and duodenogastroesopbageal reflux in gastroesophageal reflux disease. Gastroenterology 1996; 111: 1192-9
42. Cuomo R, Koek G, Sifrim D, et al. Analysis of ambulatory duodenogastroesophageal reflux monitoring. Dig Dis Sci 2000; 45: 2463-9
43. Menges M, Muller M, Zeitz M. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy. Am J Gastroenterol 2001; 96: 331-7
44. Pera M, Trastek V, Carpenter H, et al. Influence of pancreatic and biliary reflux on the development of esophageal carcinoma. Ann Thorac Surg 1993; 55: 1386-92
45. Isolauri J, Luostarinen M, Isolauri E, et al. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol 1997; 92: 37-41
46. Pace F, Santalucia F, Bianchi P. Natural history of gastrooesophageal reflux disease without oesophagitis. Gut 1991; 32: 845-8
47. Trimble K, Douglas S, Pryde A, et al. Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux. Dig Dis Sci 1995; 40: 1098-104
48. Howden C, Castell D, Cohen S, et al. The rationale for continuous maintenance treatment of reflux esophagitis. Arch Intern Med 1995; 155: 1465-71
49. Goldman M, Beckman R. Barrett syndrome: case report with discussion about concepts of pathogenesis. Gastroenterology 1960; 39: 104-10
50. Mossberg S. The columnar-lined esophagus (Barrett syndrome): an acquired condition? Gastroenterology 1966; 50: 671-6
51. Endo M, Kobayashi S, Kozu T, et al. A case of Barrett epithelialization followed up for five years. Endoscopy 1974; 4: 48-51
52. Halvorsen J, Semb B. The "Barrett syndrome" (the columnar lined lower esophagus): an acquired condition secondary to reflux esophagitis. Acta Chir Scand 1975; 141: 683-7
53. Todd J, Weston T, MacDonald T, et al. The prescribing of acid suppressants prior to the endoscopic diagnosis of Barrett's oesophagus and oesophagitis. Aliment Pharmacol 2001; 15: 221-6
54. Johansson J, Johansson F, Joelsson B, et al. Outcome five years after 360-degree fundoplication for gastroesophageal reflux disease. Br J Surg 1993; 80: 46-9
55. Ortiz A, Martinez de Haro L, Parrilla P, et al. Conservative treatment versus anti-reflux surgery in Barrett's esophagus: long term results of a prospective study. Br J Surg 1996; 83: 274-8
56. Westcher G, Gadenstaetter M, Klingler P, et al. Efficacy of medical therapy and antireflux surgery to prevent Barrett's metaptasia in patients with gastroesophageal reflux disease. Ann Surg 2001; 234: 627-32
57. Bytzer P, Christensen P, Damkier P, et al. Adenocarcinoma of the esophagus and Barrett's esophagus: a population based study. Am J Gastroenterol 1999; 94: 86-91
58. Conio M, Cameron A, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 2001; 48 (3): 304-9
59. Falk G. Unresolved issues in Barrett's esophagus in the new millenium. Dig Dis 2000; 18: 27-42
60. Shaker R. Unsedated trans-nasal pharyngoesophagogastroduodenoscopy? Gastrointest Endosc 1994; 40: 346-8
61. Craig A, Hanlon J, Dent J, et al. A comparison of transnasal and transoral endoscopy with small diameter endoscopes in unsedated patients. Gastrointest Endosc 1999; 49: 292-6
62. MacDonald C, Wicks A, Playford R. Ten years' experience of screening patients with Barrett's oesophagus in a university teaching hospital. Gut 1997; 41: 303-7
63. Provenzale D, Homan R. Screening for Barrett's esophagus in patients with GERD: can we afford the cost? Gastroenterology 2001; 96 Suppl. 278: 885
64. Soni A, Sampliner RE, Sonnenberg A. Screening for high grade dysplasia in gastroesophageal reflux disease: is it cost effective? Am J Gastroenterol 2000; 95: 2086-93
65. Iascone C, DeMeester T, Little A, et al. Barrett's esophagus, functional assessment, proposed pathogenesis and surgical therapy. Arch Surg 1983; 118: 543-9
66. Sampliner RE. Effect of up to three years of high dose lansoprazole on Barrett's. Am J Gastroenterol 1994; 89: 1844-8
67. Katzka D, Castell D. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1994; 89: 989-91
68. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997; 92: 582-5
69. Ouatu-Lascar R, Triadafilopoloulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1998; 93: 711-6
70. Peters F, Ganesh S, Kuipers E, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment: a randomised double blind study. Gut 1999; 45: 489-94
71. Fass R, Sampliner RE, Malagon I, et al. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol 2000; 14: 597-602
72. Sharma P, Weston A, Keeton S, et al. Control of esophageal acid exposure in patients with Barrett's esophagus on rabeprazole. Am J Gastroenterol 2001; 96 Suppl. 36: 110
73. Yau P, Watson D, Devitt P, et al. Laparoscopic antireflux surgery in the treatment of gastroesophageal reflux in patients with Barrett's esophagus. Arch Surg 2000; 135: 801-5
74. Farrell T, Smith C, Metreveli R, et al. Fundoplication provides effective and durable symptom relief in patients with Barrett's esophaugs. Am J Surg 1999; 178: 18-21
75. Csendes A, Braghetto I, Burdiles P, et al. Long term results of classic antireflux surgery in 152 patients with Barrett's esophagus: clinical, radiologic, endoscopic, manometric, and acid reflux test analysis before and after operation. Surgery 1998; 123: 645-57
76. Peghini P, Katz P, Castell D. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115: 1335-9
77. Ouatu-Lascar R, Fitzgerald R, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 327-35
78. Reid BJ, Levine D, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low and high risk patient subsets. Am J Gastroenterol 2000; 95: 1669-76
79. Schnell T, Sontag S, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001; 120: 1607-19
80. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997 Feb; 92 (2): 212-5
81. Wellinger J, Ollyo J, Savary M, et al. Le traitment chirurgical de endobrachyeosophage. Helv Chir Acta 1988; 55: 695-8
82. Wiliamson W, Ellis F, Gibb S, et al. Effect of antireflux operation on Barrett's mucosa. Ann Thorac Surg 1990; 49: 537-42
83. Attwood S, Barlow A, Norris T, et al. Barrett's oesophagus: effect of antireflux surgery on symptom control and development of complications. Br J Surg 1993; 79: 1050-3
84. Sagar P, Ackroyd R, Hosie K, et al. Regression and progression of Barrett's esophagus after anti-reflux surgery. Br J Surg 1995; 82: 806-10
85. McDonald M, Trastek V, Allen M, et al. Barrett's esophagus: does an antireflux procedure reduce the need for endoscopic surveillance? J Thorac Cardiovasc Surg 1996; 111: 1135-40
86. Hamilton S, Hutcheon D, Ravich W, et al. Adenocarcinoma in Barrett's esophagus after elimination of gastroesophageal reflux. Gastroenterology 1984; 86: 356-60
87. Kovacs B, Chen Y, Lewis T, et al. Successful reversal of Barrett's esophagus with multipolar electrocoagulation despite inadequate acid suppression. Gastrointest Endosc 1999; 9: 547-53
88. Sampliner RE, Camargo L, Fass R, et al. Impact of esophageal acid exposure on the endoscopic reversal of Barrett's esophagus. Am J Gastroenterol 2002; 97: 270-2
89. Sampliner RE. Ablative therapies for the columnar lined esophagus. Gastroenterol Clin North Am 1997; 26: 685-94
90. Vanlaethem J, Peny M, Salmon I, et al. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut 2000; 46: 574-7
91. Provenzale D, Kemp J, Arora S, et al. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 1994; 89: 670-80
92. Gross G, Canto M, Hixson J, et al. Management of Barrett's esophagus: a national study of practice patterns and their cost implications. Am J Gastroenterol 1999; 94: 3440-7
93. Falk G, Ours T, Richter J. Practice patterns for surveillance of Barrett's esophagus in the United States. Gastrointest Endosc 2000; 52: 197-203
94. Ackroyd R, Wakefield S, Williams J, et al. Surveillance of Barrett's esophagus: a need for guidelines? Dis Esophagus 1997; 10: 185-9
95. VanDerBurgh A, Doos J, Hop W, et al. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996; 39: 5-8
96. MacDonald C, Wicks A, Playford R. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 2000; 321: 1252-5
97. Robertson C, Mayberry J, Nicholson D, et al. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg 1988; 75: 760-3
98. Miros M, Kerlin M, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991; 32: 1441-6
99. Weston A, Badr A, Hassanein R. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high grade dysplasia or adenocarcinoma. Am J Gastroenterol 1999; 94: 3413-9
100. Buttar N, Wang K, Sebo T, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001; 120: 1630-9